Literature DB >> 23146221

Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study.

Xiemin Qi1, Li Ding, Aidong Wen, Na Zhou, Xiaolang Du, Shailendra Shakya.   

Abstract

Sometimes, drugs and their metabolites in plasma may convert to each other. This phenomenon is called interconversion, which may result in the instability problem of the plasma samples. The instability problem caused by interconversion of the co-existing metabolites may often be ignored, since there is no drug metabolite in the quality control samples prepared for method validation. Pitavastatin lactone (Pi-LAC), a main metabolite of pitavastatin (Pi), is very unstable and easily converted to Pi in plasma. In this paper, simple and rapid LC-ESI-MS/MS methods were developed for the simultaneous determination of Pi and Pi-LAC in human plasma and urine. The sample stability was examined under different conditions. The interconversion of Pi and Pi-LAC was prevented by adding a pH 4.2 buffer solution to the freshly collected plasma samples. Detection was performed using an electrospray ionization (ESI) operating in positive ion multiple reaction monitoring mode by monitoring the ion transitions from m/z 422.2→290.3 (Pi), 404.2→290.3 (Pi-LAC) and m/z 611.3→423.2 (candesartan cilextetil, the internal standard), respectively. The calibration curve of Pi and Pi-LAC in both human plasma and urine showed good linearity over the concentration range of 0.1-200 ng/mL. The established methods were successfully applied to a pharmacokinetic study of pitavastatin calcium tablets in healthy Chinese volunteers after oral administration of 1, 2 and 4 mg single and multiple doses of pitavastatin calcium. The pharmacokinetic parameters of Pi and Pi-LAC in Chinese volunteers were given respectively. The urinary excretion profiles of Pi and Pi-LAC in Chinese volunteers were also presented. After receiving a single 4 mg oral dose of pitavastatin calcium, the average cumulative urinary excretion percentages of Pi and Pi-LAC in Chinese volunteers were (0.41 ± 0.16)% and (6.1 ± 5.0)%, respectively.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146221     DOI: 10.1016/j.jpba.2012.09.026

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.

Authors:  Michelle L Montonye; Dan-Dan Tian; Tarana Arman; Katherine D Lynch; Bruno Hagenbuch; Mary F Paine; John D Clarke
Journal:  J Pharmacol Exp Ther       Date:  2019-08-16       Impact factor: 4.030

2.  Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.

Authors:  Katherine D Lynch; Michelle L Montonye; Dan-Dan Tian; Tarana Arman; Victoria O Oyanna; Baron J Bechtold; Tyler N Graf; Nicholas H Oberlies; Mary F Paine; John D Clarke
Journal:  Phytother Res       Date:  2021-02-15       Impact factor: 6.388

3.  Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.

Authors:  Jacqueline B McCrea; Azher Hussain; Bennett Ma; Graigory C Garrett; Raymond Evers; John E Laabs; S Aubrey Stoch; Marian Iwamoto
Journal:  Clin Pharmacol Drug Dev       Date:  2021-11-24

4.  Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers.

Authors:  Zhu Luo; Yunhui Zhang; Jingkai Gu; Ping Feng; Ying Wang
Journal:  Curr Ther Res Clin Exp       Date:  2015-03-03

5.  Simultaneous quantitation of folic acid and 5-methyltetrahydrofolic acid in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study.

Authors:  Xiao-Hong Zheng; Li-Yuan Jiang; Lan-Ting Zhao; Quan-Ying Zhang; Li Ding
Journal:  J Pharm Anal       Date:  2015-05-23

6.  Prediction of Clinical Transporter-Mediated Drug-Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models.

Authors:  Simon J Carter; Bhavik Chouhan; Pradeep Sharma; Michael J Chappell
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-04

7.  Protocol for systematic review and meta-analysis: impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases.

Authors:  Solima Sabeel; Bongani Motaung; Mumin Ozturk; Sandra Mukasa; Andre Pascal Kengne; Dirk Blom; Karen Sliwa; Emmanuel Nepolo; Gunar Günther; Robert J Wilkinson; Claudia Schacht; Friedrich Thienemann; Reto Guler
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.